{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T06:31:29Z","timestamp":1720852289553},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,6,14]],"date-time":"2008-06-14T00:00:00Z","timestamp":1213401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s00115-008-2486-2","type":"journal-article","created":{"date-parts":[[2008,6,12]],"date-time":"2008-06-12T18:17:25Z","timestamp":1213294645000},"page":"912-917","source":"Crossref","is-referenced-by-count":14,"title":["Langzeittherapie fokaler Dystonien und des Hemispasmus facialis mit Botulinum-Toxin\u00a0A"],"prefix":"10.1007","volume":"79","author":[{"given":"T.","family":"Vogt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"L\u00fcssi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,14]]},"reference":[{"key":"2486_CR1","first-page":"604","volume":"61","author":"Ceballos","year":"1990","unstructured":"Ceballos Baumann AO, Gasser T, Dengler R, Oertel WH (1990) Lokale Injektionsbehandlung mit Botulinumtoxin A bei Blepharospasmus, Meige Syndrom und Spasmus hemifazialis. Nervenarzt 61: 604\u2013610","journal-title":"Nervenarzt"},{"key":"2486_CR2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archneur.59.3.418","volume":"59","author":"Defazi","year":"2002","unstructured":"Defazi G, Abbruzzese G, Girlanda P et al. (2002) Botulinum toxin A treatment for primary hemifacial spasm. Arch Neurol 59: 418\u2013420","journal-title":"Arch Neurol"},{"key":"2486_CR3","first-page":"386","volume":"60","author":"Dressler","year":"1989","unstructured":"Dressler D, Benecke R, Conrad B (1989) Botulinum Toxin in der Therapie craniocervicaler Dystonien. Nervenarzt 60: 386\u2013393","journal-title":"Nervenarzt"},{"key":"2486_CR4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s004150050230","volume":"245","author":"Dressler","year":"1998","unstructured":"Dressler D, Rothwell JC, Marsden CD (1998) Comparing biological potencies of Botox and Dysport with a mouse diaphragm model may mislead. J Neurol 245: 332","journal-title":"J Neurol"},{"key":"2486_CR5","unstructured":"Dressler D, Benecke R (2004) Antik\u00f6rpervermitteltes versagen der Botulinumtoxin Therapie. In: Laskawi R, Roggenk\u00e4mper P (Hrgs) Botulinumtoxin-Therapie im Kopf-Hals-Bereich. Urban & Vogel, M\u00fcnchen"},{"key":"2486_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0039-6257(97)81995-9","volume":"41","author":"Dutton","year":"1996","unstructured":"Dutton JJ (1996) Botulinum-A toxin in the treatement of craniocervical muscle spasms: short and long-term, local and systemic effects. Surv Ophthalmol 41: 51\u201365","journal-title":"Surv Ophthalmol"},{"key":"2486_CR7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/jnnp.49.7.827","volume":"49","author":"Elston","year":"1986","unstructured":"Elston JS (1986) Botulinumtoxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry 49: 827\u2013829","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2486_CR8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/archopht.1984.01040031184014","volume":"102","author":"Frueh","year":"1984","unstructured":"Frueh BR, Felt DP, Wojno TD, Musch DC (1984) Treatment of blepharospasm with Botulinumtoxin A. A preliminary report. Arch Ophthalmol 102: 1464\u20131468","journal-title":"Arch Ophthalmol"},{"key":"2486_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"Greene","year":"1994","unstructured":"Greene P, FAhn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9: 213\u2013217","journal-title":"Mov Disord"},{"key":"2486_CR10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ana.20098","volume":"55","author":"Herrmann","year":"2004","unstructured":"Herrmann J, Geth K, Mall V et al. (2004) Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55: 732\u2013735","journal-title":"Ann Neurol"},{"key":"2486_CR11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","volume":"6","author":"Hsiung","year":"2002","unstructured":"Hsiung GYR, Das SK, Ranawaya R et al. (2002) Long term efficacy of botulinum toxin A in treatment of various movements disorders over a 10\u00a0year period. Mov Disord 6: 1288\u20131293","journal-title":"Mov Disord"},{"key":"2486_CR12","first-page":"371","volume":"16","author":"Jankovic","year":"1984","unstructured":"Jankovic J, Orman J (1984) Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 16: 371\u2013376","journal-title":"Ann Ophthalmol"},{"key":"2486_CR13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","volume":"246","author":"Kessler","year":"1999","unstructured":"Kessler KR, Skutta M, Benecke R (1999) Long term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 246: 265\u2013274","journal-title":"J Neurol"},{"key":"2486_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1212\/01.wnl.0000287087.99612.e5","volume":"70","author":"Kranz","year":"2008","unstructured":"Kranz G, Sycha T, Voller B et al. (2008) Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology 70: 133\u2013136","journal-title":"Neurology"},{"key":"2486_CR15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","volume":"78","author":"Kruisdijk","year":"2007","unstructured":"Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW et al. (2007) Botulinum toxin for writer\u2019s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 78: 264\u2013270","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2486_CR16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"Mejia","year":"2005","unstructured":"Mejia NI, Vuong KD, Jancovic J (2005) Long term botulinum toxin efficacy, safety and immunogenicity. Mov Disord 20: 592\u2013597","journal-title":"Mov Disord"},{"key":"2486_CR17","first-page":"363","volume":"4","author":"N\u00fc\u00dfgens","year":"1995","unstructured":"N\u00fc\u00dfgens Z, Roggenk\u00e4mper P (1995) Long term treatment of blepharospasm with botulinumtoxin type A. German J Ophthlamol 4: 363\u2013367","journal-title":"German J Ophthlamol"},{"key":"2486_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0002-9394(03)00075-8","volume":"136","author":"Snir","year":"2003","unstructured":"Snir M, Weinberger D, Bourla D et al. (2003) Quantitative changes in botulinum toxin A with treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 136: 99\u2013105","journal-title":"Am J Ophthalmol"},{"key":"2486_CR19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"2","author":"Tsui","year":"1986","unstructured":"Tsui JKC, Eisen A, Stoessl AJ, Calne DB (1986) Double blind study of botulinumtoxin in spasmodic torticollis. Lancet 2: 245\u2013247","journal-title":"Lancet"},{"key":"2486_CR20","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s004150170028","volume":"248","author":"Wissel","year":"2001","unstructured":"Wissel J, Kanovsky P, Ruzicka E et al. (2001) Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol 248: 1073\u20131078","journal-title":"J Neurol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-008-2486-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-008-2486-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-008-2486-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:08:33Z","timestamp":1558588113000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-008-2486-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,14]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["2486"],"URL":"https:\/\/doi.org\/10.1007\/s00115-008-2486-2","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,14]]}}}